Literature DB >> 29699428

Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.

Rodolfo Montironi1, Alessia Cimadamore1, Silvia Gasparrini1, Roberta Mazzucchelli1, Matteo Santoni2, Francesco Massari3, Liang Cheng4, Antonio Lopez-Beltran5, Marina Scarpelli1.   

Abstract

INTRODUCTION: The Gleason grading system is one of the most important prognostic factors in prostate cancer (PCa). From the 2005 to the 2014 conference organized by the International Society of Urological Pathology (ISUP), the histological criteria for the Gleason patterns were improved, resulting in the shrinkage of the Gleason pattern (GP) 3 and expansion of the GP 4. Areas Covered: Cribriform, fused, ill-defined and glomeruloid glands are part of the morphologic spectrum of the current GP 4. Cribriform, derived from the Latin word cribrum (i.e. sieve), was introduced by Gleason to describe glands composed of a solid sheet with perforations or lumina. Cribriform morphology has a worse prognosis compared with the other, non-cribriform, GP4 morphologies. A practical implication is that a cribriform growth precludes a patient from selecting an active surveillance (AS) protocol. Expert commentary: The presence of these four growth patterns should be incorporated into the current Grade Group (GG) system. Enhancing our understanding of cribriform tumor behavior will lead to correctly identifying and treating those patients that will die because of PCa, while sparing treatment in those who do not require it.

Entities:  

Keywords:  Gleason grading; Gleason pattern 4; Prostate cancer; cribriform morphology; gleason; intraductal carcinoma

Mesh:

Year:  2018        PMID: 29699428     DOI: 10.1080/14737140.2018.1469406

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  4 in total

Review 1.  [Limits of surgery in uro-oncology].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

2.  Diffusion Restriction Comparison between Gleason 4 Fused Glands and Cribriform Glands within Patient Using Whole-Mount Prostate Pathology as Ground Truth.

Authors:  Savannah R Duenweg; Xi Fang; Samuel A Bobholz; Allison K Lowman; Michael Brehler; Fitzgerald Kyereme; Kenneth A Iczkowski; Kenneth M Jacobsohn; Anjishnu Banerjee; Peter S LaViolette
Journal:  Tomography       Date:  2022-03-02

3.  Potential of the Stromal Matricellular Protein Periostin as a Biomarker to Improve Risk Assessment in Prostate Cancer.

Authors:  Valentina Doldi; Mara Lecchi; Silva Ljevar; Maurizio Colecchia; Elisa Campi; Giovanni Centonze; Cristina Marenghi; Tiziana Rancati; Rosalba Miceli; Paolo Verderio; Riccardo Valdagni; Paolo Gandellini; Nadia Zaffaroni
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

4.  In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis.

Authors:  Susanne G Kidd; Mari Bogaard; Kristina T Carm; Anne Cathrine Bakken; Aase M V Maltau; Marthe Løvf; Ragnhild A Lothe; Karol Axcrona; Ulrika Axcrona; Rolf I Skotheim
Journal:  Mol Oncol       Date:  2022-06-18       Impact factor: 7.449

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.